Despite handily beating Wall Street’s expectations for the most recent quarter and raising its 2026 earnings guidance, the healthcare giant's stock fell due to its unusually early commentary on 2027. CVS Health warned that membership in its Caremark pharmacy-benefits manager will decline next year as it rewrites contracts and some insurer clients pull back, amid broader investor concern about the evolving financial model of PBMs.